

Solid tumor and sarcoma research panels

Next-generation sequencing panels that focus on what's important. Now updated with expanded gene content.



Fusions represent an important class of biomarkers for both solid tumors and sarcomas, therefore the use of a comprehensive detection method is critical. An ideal fusion assay must be multiplexed, simple to use, and able to sensitively detect both known and novel fusions. Traditional single-biomarker fusion assays, including FISH, IHC, and RT-PCR, have several operational drawbacks and require serial testing. To save time, precious tissue sample, and increase multiplexing capabilities, labs are increasingly choosing sequencing approaches for fusion detection. However, selecting the right sequencing platform is key. DNA-based fusion detection methods typically suffer from sensitivity issues, particularly in large, low-complexity genomic regions. RNA-based assays are more sensitive in these spaces; however, some don't enable novel partner identification or require complex workflows.

FUSIONPlex®

FusionPlex panels offer a scalable and easy-to-use solution for RNA-based sequencing of solid tumors and sarcomas that meet the research needs of every lab. With **Anchored Multiplex PCR (AMP™) chemistry** at the core and an integrated bioinformatic platform, these targeted NGS panels offer a streamlined fusion detection solution from sample to data. Choose from a suite of specialized catalog panels, including **recently expanded designs for lung, sarcoma, and pan-solid tumors** that cover newly published fusion breakpoints and isoforms of interest in key gene targets, or create a custom panel to meet your exact needs.

High sensitivity fusion detection with a fast and easy workflow



Integrated bioinformatic pipeline for an end-to-end solution



Fast and flexible customization



Find your ideal NGS fusion assay

	Simple, fast workflow	Known fusion detection	Novel fusion detection	Oncogenic isoform detection	Easy panel customization
FusionPlex® AMP™ chemistry (RNA)	✓	✓	✓	✓	✓
Hybrid capture (RNA)	✗ ⁽¹⁾	✓	✓	✓	✗
Hybrid capture (DNA)	✗ ⁽¹⁾	✓	! ⁽²⁾	! ⁽⁴⁾	✗
Opposing primer amplicon (RNA)	✓	✓	! ⁽³⁾	! ⁽⁵⁾	!


! Indicates that the methodology may not be the best choice for optimal results

1. Complex library preparation processes (Hsiao et al. 2019)
2. Introns can be challenging to target and map reads to resulting in coverage gaps (Benayed et al. 2019, Davies et al. 2018)
3. Breakpoint-spanning reads are not sequenced; expression imbalance-based analyses can result in uncertainty (Vendrell et al. 2017)
4. Isoform expression cannot be evaluated using DNA input.
5. Relative mRNA abundance cannot be confirmed without Molecular Barcodes (MBCs).


Engineered for reliability.

Patented Anchored Multiplex PCR (AMP) target enrichment chemistry provides robust detection of oncogenic drivers.

- Optimized for FFPE samples
- Known and novel fusion detection
- Molecular barcode (MBC)-driven error correction and unique molecule identification




cDNA, DNA, or ctDNA fragments



Surprisingly simple NGS workflow.

Designed with simplicity in mind, easy to implement NGS research assays in any lab.

- 1.5 day library prep with minimal hands-on time
- Input requirements as low as 10ng RNA
- Lyophilized reagents to minimize error and eliminate the need for master mixes
- Single-use reactions reduce contamination
- Parallel workflow for RNA, DNA and ctDNA analysis



One powerful platform. Endless potential.

All FusionPlex assays are supported by an integrated analysis platform, Archer[®] Analysis, providing a turnkey solution to complex genomic problems.

- Simple and intuitive web-based interface
- In-line visualization for clear reporting
- Access to Quiver, our curated database of known fusion events
- Integrates LIMS data and third party providers
- Deploys securely to a cloud or local server



Introducing Archer's new FusionPlex research assays

Now with expanded gene content

FUSIONPlex®

Lung v2


Sarcoma v2

Pan Solid Tumor v2

Coverage for fusions plus additional genomic alterations



Fusions



Splicing



SNVs



Indels




Expression


Thoughtfully designed panels, updated with the most relevant gene content

- Known and novel fusions in key solid tumor and sarcoma genes including ALK, RET, ROS1, NTRK1-3, FGFR1-3, EWSR1, JAZF1, and FUS
- Oncogenic isoforms in MET Δ ex14, EGFRvIII, PDGFRA Δ 8,9, FGFR1 and KDD
- High priority SNV/Indel hotspots in EGFR, BRAF, PIK3CA, and ERBB2
- Emerging fusion and variant gene targets

Pan-solid tumor applications



Solid tumors




Sarcomas


Sensitive variant detection even with limited sample input*

Fusion and oncogenic isoform detection in FFPE reference material at low input masses

- $\geq 95\%$ sensitivity for fusions and oncogenic isoforms using 50ng TNA, 10% variant positive input by mass



Quantitative and sensitive fusion and oncogenic isoform detection down to 10% tumor cellularity



- 100% sensitivity for fusions using 50ng TNA, $\geq 10\%$ tumor cellularity
- 100% specificity for fusions using 200ng TNA input from lung, brain, colon, and lymph node (data not shown)

*Internal Archer data





Adaptable assays for tomorrow's needs

AMP chemistry powers easy customization. Archer's assays are modular, allowing them to grow and scale as your laboratory evolves over time.

AMP primers function independently, meaning new gene content can easily be added to existing panels without compromising assay performance.*

Panel size by primer number:



*Read depth must be scaled appropriately.

FusionPlex panels for solid tumor research

Compatible with Illumina® and Ion Torrent® sequencers.

Newly expanded panels:

- FusionPlex Lung v2**
 - Illumina: AB0135
 - Ion Torrent: AB0136
- FusionPlex Sarcoma v2**
 - Illumina: AB0133
 - Ion Torrent: AB0134
- FusionPlex Pan Solid Tumor v2**
 - Illumina: AB0137
 - Ion Torrent: AB0138

- Custom:** Design your own panel or add to an existing product. It's your panel, your way.



Learn more at www.archerdx.com/solid-tumor-research or email us at sales@archerdx.com

For Research Use Only. Not for use in diagnostic procedures.